@article{APS9468,
author = {Ping FENG and De-min YU and Li-ming CHEN and Bao-cheng CHANG and Qiu-di JI and Shu-ying LI and Mei ZHU and Sheng-hua DING and Baozhen ZHANG and Su-li WANG and Hong-tao LI and Jing-na LIN and Mao-jun WANG and Jian-chao GUO and Jie LIU and Zhong-dong LIU and Shentao WU and Ju-hong YANG and Clinical Cooperation Group of Liraglutid in Chinese Type 2 Diabetes},
title = {Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients},
journal = {Acta Pharmacologica Sinica},
volume = {36},
number = {2},
year = {2017},
keywords = {},
abstract = {Aim: To investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
Methods: A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 11.5 for Windows.
Results: Liraglutide treatment caused significant reduction of the mean body weight (from 86.61±14.09 to 79.10±13.55 kg) and waist circumference (from 101.81±13.96 to 94.29±14.17 cm), resulting in body weight lose of 5%–10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbA1c levels (from 8.66%±2.17% to 6.92%±0.95%) with HbA1c},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/9468}
}